NASDAQ : AXGN

AxoGen, Inc.

$44.35 USD

-$0.87 (-1.92%)

Volume
518.83K
Average Volume
1.21M
Market Capitalization
$2.38B
P/E Ratio
-65.72
Dividend Yield
0.00%
Price Target
$51.50
Year High
$46.95
Year Low
$13.50
Day High
—
Day Low
—
Payout Ratio
$0.00
Current Ratio
$6.60
Company Overview

NASDAQ

Michael D. Dale

Medical - Devices

Healthcare

AXGN

622

US

USD

https://www.axogeninc.com

386 462 6800

05463X106

0000805928

Liquidity Metrics

0.08

6.60

5.04

3.11

0.00

Sales & Valuation

$225.21M

9.49

9.23

943.91

0.05

Profitability

-$0.34

-$15.7M

-13.36%

-13.36%

-17.88%

-11.00%

P/E Metrics

-65.72

0.31

0.31

Analyst Price Target & Rating

$51.50

$55.00

$40.00

Strong Sell

1/5

19 Analysts

-13.88%

Financial Health Scores

29.22

4/9

$170M

$304.86M

$48.61M

-$21.56M

Key Metrics (TTM)

$2.36B

9.38

-159.54

6.60

-17.88%

-4.65%

-1.39%

0.10%

320 days

Company Executives
Name Title
Doris Quackenbush Chief Revenue Officer
Erick DeVinney Chief Innovation Officer
Ivica Ducic Chief Medical Officer
Craig A. Swandal Vice President of Operations
Lindsey Hartley Chief Financial Officer
Marc A. Began Executive VP, General Counsel, Secretary & Chief Compliance Officer
Michael D. Dale President, Chief Executive Officer & Director
Harold D. Tamayo Vice President of Finance & Investor Relations
Jens Schroeder Kemp Chief Marketing Officer
Rick Ditto Vice President of Global Health Economics, Reimbursement & Policy
Poll Results

No votes yet today — be the first to share your view!

About AxoGen, Inc. (NASDAQ:AXGN) Stock

AxoGen, Inc., along with its subsidiaries, specializes in creating and distributing medical devices for the surgical repair of injured or severed peripheral nerves. Their comprehensive product portfolio offers several innovative solutions. The Avance Nerve Graft is a ready-to-use, biologically active human nerve allograft designed to bridge gaps in severed nerves. This avoids the need for a second surgical site for tissue donation, thereby eliminating associated complications. For facilitating the gentle reconnection of severed peripheral nerves, the company offers the AxoGuard Nerve Connector, an extracellular matrix (ECM) derived from porcine submucosa. This same porcine submucosa ECM forms the basis of the AxoGuard Nerve Protector, which is utilized to encase and safeguard damaged perip ... heral nerves, supporting their reconstruction and preventing unwanted adhesions from surrounding soft tissues. Another ECM product, the AxoGuard Nerve Cap, isolates the nerve end from its environment to help mitigate the formation of painful neuromas. Furthermore, AxoGen provides the Avive Soft Tissue Membrane, a processed human umbilical cord membrane that functions as an absorbable covering for soft tissues, used to separate tissues within the surgical area. An additional tool available is the AxoTouch two-point discriminator, used for evaluating the density of nerve innervation on the skin's surface. These products are supplied to hospitals, surgery centers, and military medical facilities, catering to plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen's market reach extends across the United States, Canada, Germany, the United Kingdom, other European nations, South Korea, and internationally. The company's main operations are situated in Alachua, Florida.

Axogen: The Regulatory Moat Is Becoming A Commercial Flywheel

2026-08-03 02:37:45

Axogen is transforming from a niche tissue supplier into a comprehensive nerve care platform, underpinned by FDA approval, stronger reimbursement, and expanding clinical evidence. Q2 2026 revenue grew 23.1% to $69.7M, with raised full-year guidance and strong elective market traction, though gross margin declined due to product mix and biologic costs. Avance's FDA biologic approval grants 12 years of exclusivity, regulatory credibility, and improved payer coverage, positioning AXGN as a category leader with significant market opportunity.

AxoGen (NASDAQ:AXGN) Shares Gap Down Following Weak Earnings

2026-07-30 02:01:44

AxoGen, Inc. (NASDAQ: AXGN - Get Free Report)'s stock price gapped down prior to trading on Wednesday after the company announced weaker than expected quarterly earnings. The stock had previously closed at $41.15, but opened at $38.31. AxoGen shares last traded at $44.5120, with a volume of 317,776 shares trading hands. The medical equipment provider reported

Axogen, Inc. (AXGN) Q2 2026 Earnings Call Transcript

2026-07-29 14:43:24

Axogen, Inc. (AXGN) Q2 2026 Earnings Call Transcript

AxoGen Q2 Earnings Call Highlights

2026-07-29 10:05:26

AxoGen NASDAQ: AXGN reported second-quarter 2026 revenue of $69.7 million, up 23.1% from a year earlier, as demand for its Avance nerve graft and broader product portfolio increased across its target markets. The company raised its full-year revenue outlook to at least $279 million, representing growth of at least 24%, while lowering its gross-margin expectation to at least 73% due to product-mix changes tied to faster-than-expected growth in breast reconstruction.

AxoGen (AXGN) Tops Q2 Earnings and Revenue Estimates

2026-07-29 09:26:18

AxoGen (AXGN) came out with quarterly earnings of $0.12 per share, beating the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.12 per share a year ago.

Trace Biosciences Announces Strategic Investment from Axogen to Advance Clinical Development of its Nerve Trace Nerve-Specific Imaging Technology

2026-07-29 07:10:00

/PRNewswire/ -- Trace Biosciences, Inc., a clinical-stage biotechnology company developing nerve-targeted imaging agents, today announced it has received a

Axogen, Inc. Reports Second Quarter 2026 Financial Results

2026-07-29 07:05:00

ALACHUA, Fla. and TAMPA, Fla.

Axogen, Inc. to Report Second Quarter 2026 Financial Results on July 29, 2026

2026-07-15 07:00:00

ALACHUA, Fla. and TAMPA, Fla., July 15, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that it will release financial results for the second quarter of 2026 on Wednesday, July 29, 2026. Axogen management will host an investment-community conference call and webcast at 8:00 a.m. ET following the release.

Frequently Asked Questions

What is the current AxoGen, Inc. (AXGN) stock price?

AxoGen, Inc.(NASDAQ:AXGN) stock price is $44.35 in the last trading session. During the trading session, AXGN stock reached the peak price of $46.95 while $13.5 was the lowest point it dropped to. The percentage change in AXGN stock occurred in the recent session was --1.92% while the dollar amount for the price change in AXGN stock was -$0.87.

AXGN's industry and sector of operation?

The NASDAQ listed AXGN is part of Medical - Devices industry that operates in the broader Healthcare sector.

Who are the executives of AXGN?

Doris Quackenbush | Chief Revenue Officer
Erick DeVinney | Chief Innovation Officer
Ivica Ducic | Chief Medical Officer
Craig A. Swandal | Vice President of Operations
Lindsey Hartley | Chief Financial Officer

How many employees does AXGN have?

Number of AXGN employees currently stands at 622. AXGN operates from 13631 Progress Boulevard, Alachua, FL 32615, US.

Link for AXGN official website?

Official Website of AXGN is: https://www.axogeninc.com

How do I contact AXGN?

AXGN could be contacted at phone #386 462 6800 and can also be accessed through its website. AXGN operates from 13631 Progress Boulevard, Alachua, FL 32615, US.

How many shares of AXGN are traded daily?

The average number of AXGN shares traded daily for last 3 months was 1.21M.

What is the market cap of AXGN currently?

The market value of AXGN currently stands at $2.38B with its latest stock price at $44.35